Biocon's Breakthrough: Bosaya and Vevzuo Approved by Health Canada

Biocon Ltd has received approval from Health Canada for its biosimilars, Bosaya and Vevzuo, intended for treating osteoporosis and cancer-related bone complications. This approval underscores Biocon's commitment to accessible biologic therapies and enhances their global portfolio in immunology and oncology sectors.

Biocon Ltd announces a significant achievement as Health Canada grants approval for its biosimilars, Bosaya and Vevzuo. These treatments target osteoporosis and bone complications associated with cancer.

The approvals, effective April 3, 2026, mark a milestone for Biocon as it bolsters its presence in global markets.

CEO Shreehas Tambe emphasizes the company's dedication to delivering affordable biologic therapies, underscoring the role of denosumab products in enhancing bone health without compromising quality or efficacy.